Gene interactions and pathways from curated databases and text-mining

◀ Back to APOB

APOB — FGB

Text-mined interactions from Literome

Neufeld et al., Blood Coagul Fibrinolysis 2000 : In the present study, we investigate the effects of antibodies against CD11b and CD18, as well as HDL3 and low-density lipoprotein (LDL) cholesterol on fibrinogen binding on monocytes ... A slight, non-significant stimulatory effect of LDL on fibrinogen binding on ADP activated but not on Cytochalasin-B activated monocytes was additionally observed
, Platelets 1997 : Flow cytometric analysis showed that native LDL inhibited ADP induced fibrinogen binding by up to 38 % ... Fully oxidised LDL , however, inhibited ADP induced platelet aggregation and fibrinogen binding
Kobayashi et al., Ther Apher Dial 2006 (Arterial Occlusive Diseases...) : LDL-apheresis reduces P-Selectin, CRP and fibrinogen -- possible important implications for improving atherosclerosis
van Willigen et al., Arterioscler Thromb 1994 : Because previous studies show that lipoproteins affect platelet aggregation, we studied the effect of low-density lipoprotein (LDL) and high-density lipoprotein ( HDL ) on the binding of fibrinogen , which mediates platelet-platelet contact ... Neither LDL nor HDL induced 125I-fibrinogen binding at concentrations up to 2 g protein/L ... The increased fibrinogen binding in the presence of LDL resulted in faster aggregation with a 16 % increase in single platelet disappearance and a faster optical aggregation at 5 mumol/L ADP and 1.5 g protein/L LDL
PedreƱo et al., Lipids 1995 : Furthermore, LDL ( at a protein concentration of 0.3 mg/mL ) increased by 81 +/- 6 % the binding of fibrinogen to both protease- and ADP stimulated platelets, but was unable to activate fibrinogen binding sites in unstimulated platelets
Hackeng et al., Arterioscler Thromb Vasc Biol 1999 : LDL increased the surface expression of fibrinogen in lipoprotein-poor plasma and fibrinogen-free medium, suggesting that extracellular and granular fibrinogen bind to alphaIIbbeta3 after platelet-LDL interaction